Skip to main content

Fei Tang, PhD

Academic Title:

Research Associate

Primary Appointment:

Surgery

Additional Title:

Division of Immunotherapy

Location:

Institute of Human Virology, Room N270, 725 West Lombard Street, Baltimore, MD 21201

Education and Training

  • 2000-2004  B.S., Biology, Wuhan University, Wuhan, Hubei Province, China
  • 2004-2010  Ph.D., Biochemistry and Molecular Biology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
  • 2010-2013  Postdoctoral Study, Hematology and Oncoimmunology, University of Michigan Medical School, Ann Arbor, MI, USA

Biosketch

Dr. Fei Tang earned his Bachelor of Science degree in biology from Wuhan University in 2004. He completed his Ph.D. program from the CAS Key Laboratory of Infection and Immunity at the Institute of Biophysics, Chinese Academy of Sciences (CAS) in Beijing, China. In 2010, Dr. Tang went to the University of Michigan Medical School in Ann Arbor and started his postdoctoral training. In 2013, Dr. Tang moved to Washington, DC and continued his research in the fields of hematology and immunotherapy in Center for Cancer and Immunology Research at Children's National Medical Center. In early 2018, he joined the University of Maryland School of Medicine as a junior faculty member in Department of Surgery and Division of Immunotherapy, Institute of Human Virology.

Dr. Tang has made some important discoveries and published a number of papers in biomedical sciences that stretch across a wide range of research fields, including ubiquitination, autophagy, inflammation, hematopoietic stem cells, immune cell developments, tumor biology and cancer immunotherapy. Currently, Dr. Tang's major research interests are development of Chimeric Antigen Receptor (CAR) T-cell therapy, targeting mTOR signaling, PD-1/PD-L1, CTLA-4/B7 and other immune receptors/ligands to develop new modalities to better harness the immune system and advance immunotherapy of inflammatory diseases, solid tumors and hematological malignances.

 

Research/Clinical Keywords

Cancer Immunotherapy, Tumor Biology, PD-1/PD-L1, CTLA-4, Checkpoint Blockade Therapy, Chimeric Antigen Receptor (CAR) T-Cell Therapy, Immune Evasion, Inflammation, mTOR Signaling, Rapamycin, Hematopoietic Stem Cell, Hematopoiesis, Leukemia, T Cell Development, Hematopoietic Cell Fate Determination.

Highlighted Publications

  1. Tang F# and Zheng P. Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer  immunotherapy? Cell & Bioscience. 2018, 8:34 (#Correspondence author)
  2. Tang F#, Du X, Liu M, Zheng P and Liu Y. Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade? Cell & Bioscience. 2018, 8:30 (#Correspondence author)
  3. Du X*, Tang F*, Liu M, Su J, Zhang Y, Wu W, Devenport M, Lazarski CA, Zhang P, Wang X, Ye P, Wang C, Hwang E, Zhu T, Xu T, Zheng P# and Liu Y#.  A Reappraisal of CTLA-4 Checkpoint Blockade in Cancer Immunotherapy. Cell Research, 2018 Apr; 28(4): 416-432. (*Co-first authors)
  4. Tang F, Zhang P, Ye P, Lazarski CA, Wu Q, Bergin IL, Bender TP, Hall MN, Cui Y, Zhang L, Jiang T, Liu Y# and Zheng P#.  A Population of Innate Myelolymphoblastoid Effector Cell Expanded by Inactivation of mTOR Complex 1 in Mice. eLife, 2017; 6: e32497.
  5. Li CS*, Tang F*, Zhang P, Jiang T, Saunders TL, Zheng P# and Liu Y#.  Trap1a Is an X-linked and Cell-intrinsic Regulator for Thymocyte Development. Cellular & Molecular Immunology, 2017, 14: 685–692 (*Co-first authors)